BeiGene Establishes Major U.S. Biomanufacturing Hub: New Jersey Campus Marks Strategic Expansion

BeiGene has crossed a significant milestone by acquiring a 42-acre property in Hopewell, New Jersey, signaling the biotech firm’s commitment to expanding its footprint across BeiGene locations and strengthening its U.S. operations. The Princeton West Innovation Campus site will serve as home to a state-of-the-art manufacturing facility combined with clinical research and development capabilities.

Investment Scale and Timeline

The company plans to inject several hundred million dollars into the initial construction phase, creating a facility designed to span approximately 400,000 square feet. This biopharma manufacturing complex will feature up to 16,000 liters of biologics production capacity alongside dedicated research spaces. Ground-breaking is anticipated to commence in 2022, with operational status targeted for late-2023 or early-2024.

The property itself offers substantial room for growth, with over one million additional square feet available for future development—a strategic reserve that suggests BeiGene’s long-term vision for New Jersey as a core manufacturing region.

Supply Chain Diversification Strategy

BeiGene’s move represents a deliberate push to reduce dependency on single manufacturing locations and bolster its global supply chain resilience. By establishing dedicated biologic and drug candidate production capacity in the United States, the company positions itself to better serve its expanding cancer medicine pipeline while meeting regulatory requirements across different markets.

John V. Oyler, BeiGene’s Co-Founder, Chairman, and CEO, emphasized that this expansion aligns with the company’s mission to make innovative cancer treatments more accessible globally. The New Jersey location specifically supports talent recruitment efforts, tapping into the region’s established life sciences workforce.

Local Economic Impact and Industry Recognition

New Jersey’s Governor and local township leadership have highlighted the significance of this investment for the region’s biotech sector. The facility represents not just manufacturing capacity but a commitment to job creation and integration within the Princeton-Hopewell business community. This development reinforces New Jersey’s position as a growing hub for biopharmaceutical manufacturing alongside traditional research operations.

BeiGene engaged Lincoln Equities Group for the property acquisition and brought on DPR Construction and IPS as its development partners, ensuring institutional expertise in executing this complex project.

Broader Context for BeiGene

With a clinical pipeline exceeding 40 candidates and a workforce of over 7,700 professionals across five continents, BeiGene has been aggressively scaling operations to support its ambitious goal of expanding medicine access to two billion additional people by 2030. The New Jersey facility serves as a physical manifestation of this growth trajectory and represents a calculated investment in manufacturing independence and supply chain security.